{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event dictionary. The results will be tabulated to examine their frequency, organ systems affected, and relationship to study treatment. The results of laboratory assessments will be evaluated similarly.","groups":[{"description":"Carfilzomib will be administered at a dose of 20 mg/m2, with a dose escalation to 36 mg/m2 after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m2, with a dose escalation to 45 mg/m2 after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.\n\nCarfilzomib\n\nDexamethasone","id":"OG000","title":"Carfilzomib in Combination With Dexamethasone"}],"populationDescription":"Patient withdrew consent before receiving treatment","reportingStatus":"POSTED","timeFrame":"24 months","title":"Tolerability and Safety of Increasing Doses of Carfilzomib in Combination With Dexamethasone.","type":"PRIMARY"}